News
Quotient Sciences wins Medilink UK Healthcare Business Award for Outstanding Achievement
Quotient Sciences has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards.
Quotient is your answer.
Quotient is your answer.
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
-
How do I accelerate my molecule to proof-of-concept?
Learn moreLearn more
Quotient is your answer.
How do I accelerate my molecule to proof-of-concept?
Learn more -
How do I optimize my formulation?
Learn moreLearn more
Quotient is your answer.
How do I optimize my formulation?
Learn more -
How do I optimize and scale up my manufacturing process for the later stages of development and commercial launch?
Learn moreLearn more
Quotient is your answer.
How do I optimize and scale up my manufacturing process for the later stages of development and commercial launch?
Learn more -
How do I efficiently plan and execute my regulatory clinical pharmacology studies?
Learn moreLearn more
Quotient is your answer.
How do I efficiently plan and execute my regulatory clinical pharmacology studies?
Learn more -
How do I develop age-appropriate drug products for pediatric populations?
Learn moreLearn more
Quotient is your answer.
How do I develop age-appropriate drug products for pediatric populations?
Learn more
Our latest updates
Discover what’s happening at Quotient Sciences
-
Fact Sheet
Formulation Development
From preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.
-
News
Integrated Translational Pharmaceutics® Program conducted in U.S. With DRGT
Quotient Sciences, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities.